Chronic Myeloid Leukemia News

Prototype Intervention Increased Adherence to TKIs in CML

Prototype Intervention Increased Adherence to TKIs in CML

A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

Increased costs were found to be a result of more infections.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Nilotinib May Improve Rate of Deep Molecular Response in Chronic Myeloid Leukemia

Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Deep Molecular Response May Allow TKI-therapy Discontinuation in Chronic Myeloid Leukemia

Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Low-dose Dasatinib May Be Effective as Frontline Therapy in Chronic-phase Chronic Myeloid Leukemia

Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.

FDA Approves Nilotinib for Pediatric Patients With CML

FDA Approves Nilotinib for Pediatric Patients With CML

Patients one year or older are now eligible to receive the drug.

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

Ivermectin Induces Apoptosis Through Mitochondrial Dysfunction in CML Cells

A recent study sought to determine the effect of ivermectin against CML cells, whether ivermectin can sensitize cells to BCR-ABL TKIs, and its mechanism of action.

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

Molecular Response and Sokal Score Associated with Treatment-free Remission Duration in CML

A subset of patients with chronic-phase CML in the ENESTfreedom study maintained treatment-free remission for at least 96 weeks after being treatment with frontline nilotinib.

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Patients with Chronic Myeloid Leukemia at Increased Risk of Secondary Cancers

Recently published findings suggest that patients with CML, particularly men, have a 30% higher risk of developing secondary cancers; however the cause of this increased risk is unclear.

Dasatinib: A Safe and Effective Option for Pediatric CML

Dasatinib: A Safe and Effective Option for Pediatric CML

Previous studies have shown that dasatinib may be an effective therapeutic alternative to imatinib.

Pediatric CML: Imatinib Effective in the Front Line

Pediatric CML: Imatinib Effective in the Front Line

Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs